natgillin/translations-raw huggingface dataset:
The apparatus of any one of claims 10 to 16, further comprising a pressure source operatively associated with said liquid polymer supply. The apparatus of any one of claims 10 to 17, wherein said carrier comprises a drive, said drive and said controller configured to advance said carrier unidirectionally away from said build surface. 
Uređaj prema bilo kojem od zahtjeva 11 do 17, naznačen time da nadalje sadrži izvor pritiska koji je operativno spojen s navedenim dovodom tekućeg polimera. 19. Uređaj prema bilo kojem od zahtjeva 11 do 18, naznačen time da navedeni nosač sadrži pogon, gdje su navedeni pogon i navedeni upravljač konfigurirani da pomiču navedeni nosač u jednom smjeru od navedene površine za oblikovanje.
The combined organic phases were washed 1x with brine prior to drying over Na2SO4 and concentration under vacuum. 
Spojene organske faze su HR P20090113 T3 isprane 1x fiziološkom otopinom prije sušenja preko NaSO, i koncentrirane pod vakuumom.
The ophthalmic aqueous solution according to any one of claims 1 to 11 comprising at least one further pharmaceutically active substance, such as timolol. 
Oftalmološka vodena otopina prema bilo kojem od zahtjeva 1 do 4, gdje sredstvo za podešavanje pH je natrijev hidroksid i/ili klorovodonična kiselina.
providing the transmitter means with a signal for compensating residual difference in synchronization between the oscillation frequency of the oscillator circuit with respect to which these means are tuned and the universal reference signal frequency, in a second direct control loop configuration. 
- < opskrbljivanje spomenutog odašiljača (14) signalom za nadoknađivanje preostale razlike u sinhronizaciji između oscilacijske frekvencije lokalnog oscilatorskog sklopa (16), s obzirom na to koji od tih sklopova je podešen na referentni signal univerzalne frekvencije, preko druge, brze, direktne upravljačke strukture petlje, kada spora upravljačka regulacija nije dosegla konvergenciju.
A high purity diaminophenothiazinium compound of the following formula: wherein: 
PATENTNI ZAHTJEVI Diaminofenotiazinski spoj visoke čistoće koji je predstavljen sljedećom formulom:
The lozenges were made with and without buffers to achieve physiological or stability-enhancing pH values for the matrix. 
Tablete su napravljene sa ili bez pufera da bi se postigle fiziološke ili pH vrijednosti koje povećavaju stabilnosti za matriks.
The taxane containing silica was placed on 30g of clean silica gel (EM Sciences 40-63µ) and the product eluted from the silica with 4L MTBE. 
Taksan koji sadržava silicij bio je smješten na 30 g čistog silikagela (EM Sciences 40-631) i produkt je eluiran sa silicija pomoću 4L MTBE.
Cytotoxic T lymphocyte (CTL) according to Claim 11 for use in the treatment of cancer through killing target cells in a patient wherein said target cells aberrantly express a peptide according to any one of claims 1 to 5. 
Citotoksični T-limfocit (CTL) u skladu s patentnim zahtjevom 11 za uporabu u liječenju karcinoma uništavanjem ciljnih stanica u pacijentu, pri čemu ciljne stanice abnormalno predstavljaju peptid u skladu sa SEQ ID br. 2.
In the present context, the term “metastable first phase” means that the filler ingredient existing in such as phase has a free energy that is higher than the free energy of the second phase, and that an activation barrier (F*) must be overcome before transformation from the first phase (high energy state) to the second phase (low energy state) can proceed. 
U ovom kontekstu, termin "metastabilna prva faza" označuje da sastojak za punjenje koji postoji u toj fazi ima slobodnu energiju koja je viša od slobodne energije druge faze te da aktivacijska barijera (F*) mora biti prevladana prije odvijanja transformacije iz prve faze (stanje visoke energije) u drugu fazu (stanje niske energije).
a compound selected from the group consisting of a drug, a protein, a label, and a peptide, wherein said compound is conjugated to said polypeptide, or 
(B). spoj odabran iz skupine koja sadrži lijek, protein, oznaku, i peptid, pri čemu je navedeni spoj konjugiran na navedeni polipeptid, ili
The system of claim 1, wherein the control system is configured to activate the chemical application system and the degreasing system. 
Postupak prema zahtjevu 1, naznačen time što kontrolni sustav također aktivira rad usisnog uređaja.
As used herein, and only for the purposes of this application, "aerosol" is defined to include vapors, gases, particles, and the like, both visible and invisible, and especially those components perceived by the user to be "smoke-like," generated by action of the heat from the burning fuel element upon substances contained within the aerosol generating means, or elsewhere in the article. 
Kako se ovdje koristi, i samo za svrhe ove prijave, "aerosol" se definira tako da uključuje pare, plinove, djelice 1 slično, i vidljive 1 nevidljive, i naročito one komponente koje korisnik prihvaća kao komponente koje su "slične dimu", a koje su generirane djelovanjem toplote 1z izgorivog gorivog elementa iz supstanci koje se nalaze unutar sredstva za generiranje aerosola, ili magdje u proizvodu.
The compound according to any one of claims 1 to 9 which is (S)- N -(4-Fluorophenyl)-4-(4-(4-fluorophenyl)phthalazin-1-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je (S)-N-(4-fluorfenil)-4-(4-(4- fluorfenil)ftalazin-1-11)-2-metilpiperazin-1-karboksamid, ili njegova farmaceutski prihvatljiva sol.
an ether solvent that has low miscibility with water and a coordinating co-solvent, provided that the coordinating co-solvent constitutes no more than 20% v/v of the reaction mixture wherein the solubility of water in the ether solvent of (i) or (ii) that has low miscibility with water is less than 5% w/w; and wherein the ether solvent of (i) or (ii) that has low miscibility with water constitutes at least 70% v/v of the reaction mixture; 
kontakt izvodi u reakcijskoj smjesi koja sadrži: (1) koordinacijsko etersko otapalo koje ima nisku mješavost sa vodom; ili (1i) etersko otapalo koje ima nisku mješavost sa vodom i koordinacijsko ko-otapalo, uz uvjet da koordinacijsko ko-otapalo čini ne više od 20% vol.Avol. reakcijske smjese, pri čemu je otopljivost vode u eterskom otapalu (1) ili (11) koje ima nisku mješavost sa vodom manja od 5% tež./tež.; i 15
It is further disclosed that the ligno-cellulosic raw biomass stream resides in the extraction vessel for a residence time which may be in a range selected from the group consisting of 30 seconds to 300 minutes, 1 minute to 20 minutes, 2 minutes to 20 minutes, 2 minutes to 15 minutes, and 3 to 10 minutes. 
Proces iz bilo kojeg od patentnih zahtjeva 12 do 13, gdje struja ligno-celulozne neobrađene biomase se nalazi u ekstrakcijskoj posudi tijekom vremena zadržavanja koje je u opsegu odabranom iz grupe koja se sastoji od 30 sekundi do 300 minuta, 1 minute do 20 minuta, 2 minute do 20 minuta, 2 minute do 15 minuta, i 3 do 10 minuta.
concentrating the eluted protein and diafiltering against water; and 
koncentriranje razrijeđenog proteina i dijafiltriranje naspram vode (108); i
The process according to any one of claims 1-12, wherein the bile salt and biologically active polypeptide are in solution. 
Pripravak prema zahtjevu 1 ili 11, naznačen time da je navedeni biološki aktivni polipeptid odabran iz skupine koja se sastoji od inzulina, proteina YY (PYY), IFN-a, IFN-B, i IFN-Y.
The method according to claim 18, wherein the condition is selected from cancer, auto-immune diseases and immune system diseases. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time, da se koristi za liječenje karcinoma te auto-imunih bolesti i bolesti imunološkog sustava.
The present invention also provides a compound of Formula II: 
(a) reakciju spoja s formulom II:
The binding moiety of any one of claims 1 to 6 having a binding constant to C5a with a Kd value of 10 nM or less. 
C5a protutijelo ili njegov fragment koji veže antigen sukladno patentnom zahtjevu 1 ima konstantu vezanja s C5a sa Kd vrijednošću od 5 nM ili manje.
1.0ml of this solution was added to 100.7 mg of the crystalline Form I of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate. 
Cc) - opcionalno hlađenje otopine ispod 10%C; d) omogućavanje kristalizacije; i e) ioliranje kristalnog kristalnog (R)-7-kloro-N-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidroklorida monohidrata.
Airbag system for aircraft intended to protect both cabin crew and passengers, the system comprising: 
Zrakoplov koji sadrži sustav zračnih jastuka namijenjen za zaštitu putnika u putničkoj kabini i posade u kabini za posadu, naznačen time, da sustav zračnih jastuka obuhvaća:
% and an ash content of less than 0.1 wt. 
% i/ili manje od 0,1 wt.
The pharmaceutical composition for the use according to Claim 16, wherein said cancer is selected from the group consisting of breast cancer, gastrointestinal cancer, pancreas cancer, prostate cancer, ovarian cancer, stomach cancer, endometrial cancer, salivary gland cancer, lung cancer, kidney cancer, colon cancer, colorectal cancer, thyroid cancer, bladder cancer, glioma, melanoma, carcinoma, in particular epithelial or squamous carcinoma, other HB-EGF expressing or overexpressing cancers, and formation of tumor metastases. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 16, pri čemu je navedeni rak odabran iz grupe koju čine rak dojke, rak gastrointestinalnog trakta, rak gušterače, rak prostate, rak jajnika, rak želuca, rak endometrija, rak žlijezda slinovnica, rak pluća, rak bubrega, rak debelog crijeva, kolorektalni rak, rak štitne žlijezde, rak HR P20130903 T1 mjehura, gliom, melanom, karcinom, posebno epitelni iliskvamozni karcinom, druge vrste raka koje eksprimiraju ili pojačano eksprimiraju HB-EGF i stvaranje metastaza tumora.
Further provided is therefore a method according to the invention, wherein the target epitope recognized by the variable regions of the 3rd and 4th CH3 domain comprising polypeptide chain is the same, but different from the target epitope recognized by the variable region of the or the 2nd CH3-domain comprising polypeptide chain. 
Postupak u skladu patentnim zahtjevom 9, naznačen time što je ciljni epitop kojeg prepoznaju varijabilne regije trećeg 1 četvrtog polipeptidnog lanca koji sadrži CH3 domenu istu kao ciljni epitop kojeg prepoznaje varijabilna regija prvog ili drugog polipeptidnog lanca koji sadrži CH3 domenu.
N-terminal hydrophilic fragment Soybean 7S Globulin a' Subunit The fragment according to claim 1, consisting of 142 amino acid residues from said N-terminal side. 
N-terminalni hidrofilni fragment a' podjedinice 7S globulina sjemenke soje, naznačen time da se sastoji od 142 aminokiselinska ostatka od rečenog N-terminalnog kraja.
treating the film layer with a hydrophilic solvent to self-assemble bilirubin nanoparticles. 
obrađivanje sloja filma s hidrofilnim otapalom da se samostalno sastave čestice bilirubina.
Het as a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing I to 4 heteroatomseach independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally condended with a benzene ring; and wherein said het as a whole is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, amino, mono- or di-C1-6alkylamino, azido, mercapto, polyhaloC1-6alkyl, polyhaloC1-6alkoxy, C3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C1-6alkylpiperazinyl, 4-C1-6alkylearbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C1-6alkyl radicals. 
Het kao skupina ili kao dio skupine je 5- ili 6-člani zasićeni, djelomično nezasićeni ili u cijelosti nezasićeni heterociklički prsten koji sadrži 1 do 4 heteroatoma od kojih je svaki nezavisno odabran iz dušika, kisika i sumpora, pri čemu je navedeni heterociklički prsten proizvoljno kondenziran sa nekim benzenskim prstenom; i pri čemu navedeni het je u cijelosti proizvoljno supstituiran sa jednim, dva ili tri supstituenta od kojih je svaki nezavisno odabran iz skupine koja se sastoji od halo, hidroksi, nitro, cijano, karboksila, Ci.galkila, C,salkoksi, Cy.galkoksiC.. salkila, Ci .salkilkarbonila, amino, mono- ili di-C,.salkilamino, azido, merkapto, polihaloC; salkila, polihaloC.. salkoksi, CagCikloalkila, pirolidinila, piperidinila, piperazinila,
is a hydrogen atom, a lower alkyl group optionally substituted by one or more lower alkoxy groups, a lower alkanoyl group, a lower alkylsulfonyl group, or a phenyl lower alkyl group; 
R* je atom vodika, C; alkil skupina opcijski supstituirana s jednom ili više C;.4 alkoksi skupina, C;.4 alkanoil skupina, Ci. alkilsulfonil skupina, ili fenil C;.4 alkil skupina;
A method according to claim 44, wherein said at least one carboxylic acid comprises at least one carboxylic acid having a chain length corresponding to 1-4 carbon atoms. 
Metoda u skladu s patentnim zahtjevom 44, pri čemu navedena barem jedna karboksilna kiselina obuhvaća barem jednu karboksilnu kiselinu koja ima određenu dužinu koja odgovara 1-4 atoma ugljika.
Process according to Claim 6, characterized in that the amount of calcium in the ingredients used for the pharmaceutical solution, namely the chelate powder, in particular DOTA, water and meglumine, is less than 50 ppm, advantageously less than 20 ppm. 
Postupak prema zahtjevu 8, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji koja se daje pacijentu manja od 50 ppm i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu u koraku b), odnosno za DOTA prašak, vodi i megluminu, manja od 20 ppm, poželjno manja od 15 ppm.
A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt, or prodrug thereof and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se + iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
It should be noted that the laser sensitive material may comprise an ink. 
Sklop za identifikaciju prema patentnom zahtjevu 7, pri čemu materijal osjetljiv na uporabu lasera (26) sadrži tintu.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
The composition according to claim 6, wherein the poloxamer 407 (Pluronic F127®) concentration is from 0.1 to 4% (w/v), wherein the serum albumin concentration is from 0.001 to 3% (w/v) and the trehalose concentration is from 5 to 50% (w/v). 
Pripravak u skladu s patentnim zahtjevom 6, naznačen time što se koncentracija poloksamera 407 (Pluronic F127®) kreće od 0,1 do 4% (tež./vol.), koncentracija seralbumina se kreće od 0,001 do 3% (tež./vol.), a koncentracija trehaloze se kreće od 5 do 50% (tež./vol.).
The process according to claim 1, wherein in step d) the calcium carbonate is first contacted with the at least one acid having a pKa of less than or equal to 2.5 and after 80% of the total amount of said at least one acid having a pKa of less than or equal to 2.5 have been added, the calcium carbonate is contacted with the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid. 
Postupak prema zahtjevu 10, naznačen time da se kalcijev karbonat prvo dovodi u kontakt sa najmanje jednom kiselinom koja ima pK, od manje od ili jednako 2.5 i nakon što je dodano 80 % ukupne količine navedene najmanje jedne kiseline koja ima pK, od manje od ili jednako 2.5, kalcijev karbonat se dovođi u kontakt sa barem jednom u vodi topivom ne-polimernom organskom i/ili anorganskom slabom kiselinom i/ili vodikovom soli navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline.
A method as claimed in any of claims 10 to 13, wherein the fresh response includes a false address to cause the message to be sent to a smart services control node, and wherein said node is the message controller or a different network element such as a different message controller, and/or wherein the node is one of a plurality of message controllers which is dynamically selected. 
HR P20171344 T1 Postupak prema bilo kojem od zahtjeva 10 do 13, pri čemu novi odgovor sadrži lažnu adresu kako bi se dovelo do toga da se poruka pošalje ka kontrolnom čvoru za pametne servise i pri čemu je navedeni čvor kontroler poruka ili neki različiti mrežni element, kao što je neki drugi kontroler poruka, i/ili pri čemu je čvor jedan od većeg broja kontrolera poruka koji se dinamički odabira.
The carrier of claim 4, wherein the molecular sieve has window openings of 4Å diameter. 
Nosač prema zahtjevu 3, gdje molekularno sito ima prozorčiće otvore promjera 4Å.
The compounds of the present invention are useful in the treatment and/or prevention of diseases or condition relates to hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component. 
Spojevi prema ovom izumu korisni su u liječenju i(li) sprječavanju bolesti ili stanja koja se odnose na hiperglikemiju, dislipidemiju, dijabetes tip II, dijabetes tip 1, hipertrigliceridmiju, sindrom X, otpornost na inzulin, srčanu insuficijenciju, dijabetičnu dislipidemiju, hiperlipidemiju, hiperkolesteremiju, hipertenziju, pretilost, anoreksiju bulimiju, anoreksiju nervozu, kardiovaskularne bolesti i druge bolesti čija je komponenta otpornost na inzulin.
The invention proposes a device for the production of sodium hypochlorite or of hypochlorous acid for water treatment, the device being suitable for being connected directly to a pipeline of water to be treated under pressure, the device comprising: 
Uređaj (40) za proizvodnju natrijevog hipoklorita ili hipoklorne kiseline za obradu vode, pri čemu je navedeni uređaj (40) namijenjen za spajanje na kanalizacijski vod za obradu vode pod tlakom u sustavu za pročišćavanje vode, navedeni uređaj (40) sadrži:
wherein the ring system as a whole may be substituted by one or more C1-6alkyl or (CH2)aC3-6cycloalkyl groups. 
DN pri čemu sustav prstena u cjelini može biti supstituiran s jednom 1li više od sljedećih skupina: C,galkil ili (CH2),C3. zcikloalkil.
Examples of cyclosporine derivatives are those disclosed in WO99/18120. 
Primjeri ciklosporinskih derivata su oni objavljeni u WO99/18120.
L is absent, the linking group with the reactive group bonded thereto, a polyethylene glycol unit (-OCH2CH2)n-, a linear, branched or cyclic alkyl or alkenyl having 1 to 10 carbon atoms, a phenyl group, a 3 to 18-membered heterocyclic ring or a 5- to 18-membered heteroaryl ring having 1 to 6 heteroatoms independently selected from O, S, N and P, wherein the alkyl or alkenyl is optionally substituted with the linking group with the reactive group bonded thereto; phenyl or heterocyclic or heteroaryl ring can be optionally substituted, wherein the substituent can be the linking group with the reactive group bonded thereto; M is -H or a cation; 
L nema, ili je vezna skupina s vezanom reaktivnom skupinom na sebi, jedinica polietilen glikola (-OCH2CH2)n-, linearni, razgranati ili ciklički alkil ili alkenil s 1 do 10 atoma ugljika, fenilna skupina, 3 do 18-eročlani heterociklički prsten ili 5- do 18-eročlani heteroarilni prsten s 1 do 6 heteroatoma koji su nezavisno izabrani između O, S, N i P, gdje je alkil ili alkenil po izboru supstituiran s veznom skupinom na koju je vezana reaktivna skupina; fenil ili heterociklički ili heteroarilni prsten mogu po izboru biti supstituirani, gdje supstituent može biti vezna skupina s vezanom reaktivnom skupinom na sebi; uz uvjet da spoj nije niti jedan od sljedećih spojeva: [image] [image]
6 provides additional details of the connection of the outputs of the receiver to the electronic engine controls. 
Slika 6 prikazuje dodatne pojedinosti o priključivanju izlaza prijemnika na elektronske kontrole motora.
The method of any one of claims 1 to 10, wherein the (±)-A9-tetrahydrocannabinol comprises at least about 95% by weight, preferably at least about 98% by weight and more preferably at least about 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 7 do 10, naznačen time da (±)-A9-tetrahidrokanabinol sadrži barem 95% težinski, poželjno barem 98% težinski i poželjnije barem 99% težinski trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
A pharmaceutical composition for use in the method of any one of claims 1 to 4, wherein the patient, following the administration of the pharmaceutical composition, exhibits an improvement in one or more atopic dermatitis (AD)-associated parameter, wherein the improvement in the one or more AD-associated parameter is a decrease from baseline in: IGA of at least 50% on day 29 after administration of the antibody or antigen-binding fragment thereof that binds IL-4R; 
Farmaceutski pripravak za primjenu u metodi prema zahtjevu 10, naznačen time, što je poboljšanje parametra povezanog s AD-om: smanjenje rezultata IGA za najmanje 35 % u odnosu na osnovicu do 22. dana nakon primjene prve doze farmaceutskog pripravka koji sadrži antitijelo protiv humanog IL-4R ili njegov fragment koji se vezuje za antigen;
Finally, the aerodynamics of the trolleys of the wind system 1 is better, since the aerodynamic friction due to the recovering systems 8 is not present any more. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da spomenuta opruga bude pritisnuta zbog djelovanja napetosti spomenutog užeta (4).
a solid state 13C NMR spectrum having substantially similar peak positions at 16.2,17.6, 39.3, 60.9, 63.3, 69.8, 76.9, 78.7, 79.4, 113.8, 123.6, 129.3, 130.5, 132.0, 135.7, 139.1 and 158.0 ppm, as determined on a 400MHz spectrometer relative to TMS at zero; a differential scanning calorimetry thermogram having an endotherm in the range of about 50°C to 78°C or as shown in Figure 7; 
CC NMR spektar čvrstog stanja koji ima u suštini slične položaje pikova kod 16.2,17.6, 39.3, 60.9, 63.3, 69.8, 76.9, 78.7, 794, 113.8, 123.6, 129.3, 130.5, 132.0, 135.7, 139.1 i 158.0 ppm, kao što je određeno 400 MHz spektrometrom u odnosu prema TMS na nuli; termogram diferencijalne pretražne kalorimetrije koji ima endotermu u rasponu od oko 50*C do 78*C ili kako je prikazano na slici 7;
A non-selective beta blocker for example alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propafenone (propafenone is a sodium channel blocking drug that also is a beta-adrenergic receptor antagonist), propranolol, sotalol, timolol or pharmaceutically acceptable salts therof, or a mixture thereof, is disclosed. 
3. Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je ne-selektivni beta blokator odabran iz skupine koja se sastoji od alprenolola, karteolola, levobunolola, mepindolola, metipranolola, nadolola, oksprenolola, penbutolola, pindolola, sotalola, timolola, njihovih farmaceutski prihvatljivih soli i smjesa.